The Effect of Statins on Ocular Disorders: A Systematic Review of Randomized Controlled Trials

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 May 27

PMID 37242493

Authors

Charoula Lymperopoulou

Stylianos A Kandarakis

Ismini Tzanaki

Ioanna Mylona

Theodoros Xanthos

Aris P Agouridis

Affiliations

Soon will be listed here.

Abstract

Aim: Statins have been established in the market not only due to their ability to lower plasma cholesterol levels but also due to their pleiotropic effects. In the literature, there is a controversy regarding the role of statins in ophthalmology. We aimed to systematically address the possible effect of statin therapy on ocular diseases and to identify if there is a beneficial relationship.

Methods: We searched PubMed and Cochrane Library databases up to 31 December 2022 for studies evaluating the effect of statins on ocular diseases. We included all relevant Randomized Control Trials (RCTs) that have been conducted in the adult population. PROSPERO registration number: CRD42022364328.

Results: Nineteen RCTs were finally considered eligible for this systematic review, with a total of 28,940 participants. Ten studies investigated the role of simvastatin, suggesting a lack of cataractogenic effect and a possible protective role in cataract formation, retinal vascular diseases, and especially diabetic retinopathy, age-related macular disease progression, and non-infectious uveitis. Four studies investigated lovastatin, showing no cataractogenic effect. Three studies examined atorvastatin, revealing conflicting results regarding diabetic retinopathy. Two studies examined rosuvastatin, indicating a possibly harmful effect on lenses and a significant protective effect on retinal microvasculature.

Conclusions: Based on our findings, we believe that statins have no cataractogenic effect. There are indications that statins may have a protective role against cataract formation, AMD, diabetic retinopathy progression, and non-infectious uveitis. However, our results were insufficient for any robust conclusion. Future RCTs, with large sample sizes, on the current topic are therefore recommended to provide more solid evidence.

Citing Articles

The role of cholesterol crystals and ocular crystal emboli in retinal pathology.

Medawar N, Dorweiler T, Abela G, Busik J, Grant M Am Heart J Plus. 2024; 47:100475.

PMID: 39493444 PMC: 11530860. DOI: 10.1016/j.ahjo.2024.100475.

Bottlenecks in the Investigation of Retinal Sterol Homeostasis.

Ramachandra Rao S, Fliesler S Biomolecules. 2024; 14(3.

PMID: 38540760 PMC: 10968604. DOI: 10.3390/biom14030341.

References

Bang C, Greve A, La Cour M, Boman K, Gohlke-Barwolf C, Ray S . Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study). Am J Cardiol. 2015; 116(12):1840-4. DOI: 10.1016/j.amjcard.2015.09.026. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Pedersen T, Berg K, Cook T, Faergeman O, Haghfelt T, Kjekshus J . Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996; 156(18):2085-92. View

HAVEL R, Hunninghake D, Illingworth D, Lees R, Stein E, Tobert J . Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann Intern Med. 1987; 107(5):609-15. DOI: 10.7326/0003-4819-107-5-609. View

Ozkiris A, Erkilic K, Koc A, Mistik S . Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy. Br J Ophthalmol. 2006; 91(1):69-73. PMC: 1857585. DOI: 10.1136/bjo.2006.098285. View

Ooi K, Khoo P, Vaclavik V, Watson S . Statins in ophthalmology. Surv Ophthalmol. 2019; 64(3):401-432. DOI: 10.1016/j.survophthal.2019.01.013. View

Maguire M, Ying G, McCannel C, Liu C, Dai Y . Statin use and the incidence of advanced age-related macular degeneration in the Complications of Age-related Macular Degeneration Prevention Trial. Ophthalmology. 2009; 116(12):2381-5. PMC: 2787900. DOI: 10.1016/j.ophtha.2009.06.055. View

Agouridis A, Elisaf M, Nair D, Mikhailidis D . All for Statins and Statins for All; An Update. Curr Pharm Des. 2015; 22(1):18-27. DOI: 10.2174/1381612822666151109111511. View

Weis M, Heeschen C, Glassford A, Cooke J . Statins have biphasic effects on angiogenesis. Circulation. 2002; 105(6):739-45. DOI: 10.1161/hc0602.103393. View

10.

Chew E, Davis M, Danis R, Lovato J, Perdue L, Greven C . The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014; 121(12):2443-51. PMC: 4252767. DOI: 10.1016/j.ophtha.2014.07.019. View

11.

Sasaki M, Gan W, Kawasaki R, Hodgson L, Lee K, Wong T . Effect of simvastatin on retinal vascular caliber: the Age-Related Maculopathy Statin Study. Acta Ophthalmol. 2013; 91(5):e418-9. DOI: 10.1111/aos.12114. View

12.

Yuan Y, Xiong R, Wu Y, Ha J, Wang W, Han X . Associations of statin use with the onset and progression of open-angle glaucoma: A systematic review and meta-analysis. EClinicalMedicine. 2022; 46:101364. PMC: 8987630. DOI: 10.1016/j.eclinm.2022.101364. View

13.

Blanco-Colio L, Tunon J, Martin-Ventura J, Egido J . Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2002; 63(1):12-23. DOI: 10.1046/j.1523-1755.2003.00744.x. View

14.

Bach L, Cooper M, OBrien R, Jerums G . The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis. J Am Geriatr Soc. 1990; 38(1):10-4. DOI: 10.1111/j.1532-5415.1990.tb01589.x. View

15.

Toth P, Banach M . Statins: Then and Now. Methodist Debakey Cardiovasc J. 2019; 15(1):23-31. PMC: 6489607. DOI: 10.14797/mdcj-15-1-23. View

16.

Laties A, SHEAR C, Lippa E, Gould A, Taylor H, Hurley D . Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin. Am J Cardiol. 1991; 67(6):447-53. DOI: 10.1016/0002-9149(91)90002-3. View

17.

Newman C, Preiss D, Tobert J, Jacobson T, Page 2nd R, Goldstein L . Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2018; 39(2):e38-e81. DOI: 10.1161/ATV.0000000000000073. View

18.

Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

19.

Murakami T, Kato S, Shigeeda T, Itoh H, Komuro I, Takeuchi M . Intensive treat-to-target statin therapy and severity of diabetic retinopathy complicated by hypercholesterolaemia. Eye (Lond). 2020; 35(8):2221-2228. PMC: 8302652. DOI: 10.1038/s41433-020-01202-5. View

20.

Yu S, Chu Y, Li G, Ren L, Zhang Q, Wu L . Statin Use and the Risk of Cataracts: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017; 6(3). PMC: 5523994. DOI: 10.1161/JAHA.116.004180. View